Can I read Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer on EtoBox?

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer by Cipriano, Élia (author);Mesquita, Alexandra (author) is a Medicine article available to read on EtoBox.

What is Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer about?

Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and currently with few treatment options. Treatment of these patients is highly based on systemic chemotherapy. Some targeted drugs were recently approved for these patients: two poly(ADP-ribose) polymerase inhibitors in patients with germline BRCA1/2 mutations (olaparib and talazoparib), immune checkpoint inhibitors in association with chemotherapy if programmed death-ligand 1 positive (atezolizumab plus nabpaclitaxel and pembrolizumab plus chemotherapy [nabpaclitaxel, paclitaxel, and carboplatin plus gemcitabine]), and an antibody-drug conjugate sacituzumab-govitecan in heavily pretreated patients (at least 2 previous lines for the metastatic setting). Combinations using these and other targeted treatment options are under investigation in early and late clinical trials, and we will probably have some practice-changing results in the new future. Other targeted drugs explored in phase II and phase III clinical trials are PI3K/AKT pathway inhibitors and androgen receptor antagonists in patients with alterations in these signaling pathways. The definition of molecular subtypes has been e

Who reads Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer?

Author

Cipriano, Élia (author);Mesquita, Alexandra (author)

Publisher

SAGE Publications

Published

2021

Language

EN

Field

Medicine (Health Sciences)